LeonaBio Net Income
| LONA Stock | 4.72 0.07 1.51% |
As of the 5th of February, LeonaBio secures the Mean Deviation of 4.09, downside deviation of 4.49, and Risk Adjusted Performance of 0.0499. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of LeonaBio, as well as the relationship between them.
LeonaBio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing LeonaBio's valuation are provided below:We have found one hundred fifteen available fundamental ratios for LeonaBio, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of LeonaBio last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of February 5, 2026, Market Cap is expected to decline to about 24.7 M. The current year's Enterprise Value is expected to grow to about (26.9 M) This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -87.2 M | -91.6 M | |
| Net Loss | -87.2 M | -91.6 M | |
| Net Loss | (28.97) | (30.42) |
LeonaBio | Net Income | Build AI portfolio with LeonaBio Stock |
Analyzing LeonaBio's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing LeonaBio's current valuation and future prospects.
Latest LeonaBio's Net Income Growth Pattern
Below is the plot of the Net Income of LeonaBio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in LeonaBio financial statement analysis. It represents the amount of money remaining after all of LeonaBio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is LeonaBio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LeonaBio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (96.94 M) | 10 Years Trend |
|
Net Income |
| Timeline |
LeonaBio Net Income Regression Statistics
| Arithmetic Mean | (36,173,371) | |
| Coefficient Of Variation | (119.34) | |
| Mean Deviation | 38,460,950 | |
| Median | (5,097,000) | |
| Standard Deviation | 43,169,444 | |
| Sample Variance | 1863.6T | |
| Range | 112.6M | |
| R-Value | (0.84) | |
| Mean Square Error | 592.5T | |
| R-Squared | 0.70 | |
| Significance | 0.000027 | |
| Slope | (7,162,457) | |
| Total Sum of Squares | 29817.6T |
LeonaBio Net Income History
Other Fundumenentals of LeonaBio
LeonaBio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for LeonaBio is extremely important. It helps to project a fair market value of LeonaBio Stock properly, considering its historical fundamentals such as Net Income. Since LeonaBio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of LeonaBio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of LeonaBio's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LeonaBio. Expected growth trajectory for LeonaBio significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive LeonaBio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding LeonaBio requires distinguishing between market price and book value, where the latter reflects LeonaBio's accounting equity. The concept of intrinsic value - what LeonaBio's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push LeonaBio's price substantially above or below its fundamental value.
Understanding that LeonaBio's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LeonaBio represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LeonaBio's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
LeonaBio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to LeonaBio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of LeonaBio.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in LeonaBio on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding LeonaBio or generate 0.0% return on investment in LeonaBio over 90 days. LeonaBio is related to or competes with Citius Pharmaceuticals, SeaStar Medical, Apollomics, Moleculin Biotech, Curis, FibroBiologics Common, and Lunai Bioworks. LeonaBio is entity of United States. It is traded as Stock on NASDAQ exchange. More
LeonaBio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure LeonaBio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess LeonaBio upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.49 | |||
| Information Ratio | 0.0482 | |||
| Maximum Drawdown | 71.83 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 6.7 |
LeonaBio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for LeonaBio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as LeonaBio's standard deviation. In reality, there are many statistical measures that can use LeonaBio historical prices to predict the future LeonaBio's volatility.| Risk Adjusted Performance | 0.0499 | |||
| Jensen Alpha | 0.4951 | |||
| Total Risk Alpha | (0.18) | |||
| Sortino Ratio | 0.0955 | |||
| Treynor Ratio | (2.13) |
LeonaBio February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0499 | |||
| Market Risk Adjusted Performance | (2.12) | |||
| Mean Deviation | 4.09 | |||
| Semi Deviation | 4.04 | |||
| Downside Deviation | 4.49 | |||
| Coefficient Of Variation | 1804.65 | |||
| Standard Deviation | 8.89 | |||
| Variance | 79.07 | |||
| Information Ratio | 0.0482 | |||
| Jensen Alpha | 0.4951 | |||
| Total Risk Alpha | (0.18) | |||
| Sortino Ratio | 0.0955 | |||
| Treynor Ratio | (2.13) | |||
| Maximum Drawdown | 71.83 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 6.7 | |||
| Downside Variance | 20.12 | |||
| Semi Variance | 16.36 | |||
| Expected Short fall | (4.98) | |||
| Skewness | 5.39 | |||
| Kurtosis | 36.73 |
LeonaBio Backtested Returns
LeonaBio appears to be very risky, given 3 months investment horizon. LeonaBio has Sharpe Ratio of 0.0717, which conveys that the firm had a 0.0717 % return per unit of risk over the last 3 months. By analyzing LeonaBio's technical indicators, you can evaluate if the expected return of 0.66% is justified by implied risk. Please exercise LeonaBio's Downside Deviation of 4.49, risk adjusted performance of 0.0499, and Mean Deviation of 4.09 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, LeonaBio holds a performance score of 5. The company secures a Beta (Market Risk) of -0.23, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning LeonaBio are expected to decrease at a much lower rate. During the bear market, LeonaBio is likely to outperform the market. Please check LeonaBio's semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether LeonaBio's current price movements will revert.
Auto-correlation | -0.25 |
Weak reverse predictability
LeonaBio has weak reverse predictability. Overlapping area represents the amount of predictability between LeonaBio time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of LeonaBio price movement. The serial correlation of -0.25 indicates that over 25.0% of current LeonaBio price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.25 | |
| Spearman Rank Test | 0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 1.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
LeonaBio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, LeonaBio reported net income of (96.94 Million). This is 128.4% lower than that of the Healthcare sector and 238.4% lower than that of the Biotechnology industry. The net income for all United States stocks is 116.98% higher than that of the company.
LeonaBio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LeonaBio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LeonaBio could also be used in its relative valuation, which is a method of valuing LeonaBio by comparing valuation metrics of similar companies.LeonaBio is currently under evaluation in net income category among its peers.
LeonaBio Fundamentals
| EBITDA | (95.81 M) | ||||
| Net Income | (96.94 M) | ||||
| Total Debt | 1.22 M | ||||
| Cash Flow From Operations | (97.17 M) | ||||
| Number Of Employees | 26 | ||||
| Total Asset | 58.78 M | ||||
| Retained Earnings | (406.15 M) | ||||
| Working Capital | 41.71 M | ||||
| Net Asset | 58.78 M |
About LeonaBio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze LeonaBio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LeonaBio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LeonaBio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether LeonaBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of LeonaBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Leonabio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Leonabio Stock:Check out For information on how to trade LeonaBio Stock refer to our How to Trade LeonaBio Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LeonaBio. Expected growth trajectory for LeonaBio significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive LeonaBio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding LeonaBio requires distinguishing between market price and book value, where the latter reflects LeonaBio's accounting equity. The concept of intrinsic value - what LeonaBio's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push LeonaBio's price substantially above or below its fundamental value.
Understanding that LeonaBio's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LeonaBio represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LeonaBio's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.